Abstract
Dopamine reuptake blockers, by enhancing and stabilizing intrasynaptic transmitter levels, could help palliate motor dysfunction in Parkinson's disease. This randomized, double-blind, placebo-controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients. At the dose administered, no change in parkinsonian scores was found when NS 2330 was given alone or with levodopa. Moreover, NS 2330 coadministration did not appear to alter dyskinesia severity or the duration of the antiparkinsonian response to levodopa. The drug was well tolerated. Under the conditions of this study, the present results failed to support the usefulness of dopamine reuptake inhibition in the treatment of advanced Parkinson's disease.
(c) 2004 Movement Disorder Society.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antiparkinson Agents / therapeutic use*
-
Benzothiazoles
-
Carbidopa / therapeutic use
-
Dopamine Plasma Membrane Transport Proteins
-
Dopamine Uptake Inhibitors / therapeutic use*
-
Double-Blind Method
-
Drug Combinations
-
Drug Therapy, Combination
-
Female
-
Humans
-
Indoles / therapeutic use
-
Levodopa / therapeutic use
-
Male
-
Membrane Glycoproteins
-
Membrane Transport Proteins
-
Middle Aged
-
Nerve Tissue Proteins
-
Parkinson Disease / diagnosis
-
Parkinson Disease / drug therapy*
-
Pilot Projects
-
Pramipexole
-
Thiazoles / therapeutic use
Substances
-
Antiparkinson Agents
-
Benzothiazoles
-
Dopamine Plasma Membrane Transport Proteins
-
Dopamine Uptake Inhibitors
-
Drug Combinations
-
Indoles
-
Membrane Glycoproteins
-
Membrane Transport Proteins
-
Nerve Tissue Proteins
-
Thiazoles
-
carbidopa, levodopa drug combination
-
ropinirole
-
Levodopa
-
Pramipexole
-
Carbidopa